Search This Blog

Thursday, April 20, 2023

Biden's Fired They/Them Luggage-Stealing Nuke Official To Undergo Mental Health Evaluation

 Sam Brinton, the Biden administration's fired luggage-stealing nuke official who was busted wearing a fashion designer's clothes he stole from her luggage, will undergo a mental health evaluation as part of an adult diversion program in Minnesota.

Brinton, who identifies as nonbinary and uses "they/them" pronouns was ordered to undergo the treatment after a Monday hearing at the Hennepin County Court, which stemmed from a September luggage theft incident at Minneapolis St. Paul International Airport, Fox9 reported. Brinton will also need to write a letter of apology to the victim, return any stolen property, and perform three days of community service under the program for adult, first-time, nonviolent offenders.

Illinois Lawmaker Calls Weekend Chaos A 'Mass Protest'

 After a flash mob of more than 500 youths trashed downtown Chicago last weekend, smashing and setting fire to cars, terrorizing tourists, smashing windows and fighting in a riot that left two teenage boys hospitalized with gunshot wounds (albeit a common occurrence), one Democratic leader is making excuses.

Via the Daily Mail

Near-death experiences among ICU survivors

 Research on the incidence of near-death experiences (NDEs) in patients admitted to intensive care units (ICU) for at least 7 days reveals that 15% reported having experienced a NDE. The emergence of these experiences seems to be enhanced by the propensity for dissociative symptoms and by the patients' spiritual beliefs and practices.

As stated by Bruce Greyson, NDEs are "intensely vivid and often life-transforming experiences, often occurring under extreme physiological conditions such as life-threatening trauma, , or deep anesthesia." To date, few prospective studies on NDE were carried out only in ICU patients with homogeneous aetiologies, such as cardiac arrest or trauma survivors.

It was in this context that researchers from the Universities of Liège (Belgium) and Laval (Canada) carried out a study to assess the incidence of NDEs among ICU survivors, regardless of the critical illness they survived. The research also covered the factors that may affect the frequency of NDEs and evaluated the patients' quality of life one year after the experience.

The findings are published in the journal Critical Care.

The study included 126 adult participants with more than 7 days of ICU stays, who were interviewed after discharge. Of this sample, 19 patients (15%) reported having experienced a NDE as assessed by the NDE scale created by Greyson. Participants were further assessed for dissociative experiences, spirituality, religiosity and personal beliefs, as well as for dozens of medical parameters. One year later, they were contacted by phone to measure their quality of life, using the EuroQol five-dimensional questionnaire.

In the article, the team led by Charlotte Martial and Anne-Françoise Rousseau reveals that in the study carried out, in addition to a 15% NDE incidence, cognitive and spiritual factors outweighed medical parameters as predictors of the emergence of NDE.

While the univariate analyses associated , sedation, analgesia, reason for admission, primary organ dysfunction, and dissociative and spiritual propensities with NDE emergence, the multivariate logistic regression analysis only indicated a greater propensity for dissociative symptoms and a greater spiritual and personal well-being as predicted factors for NDE emergence. An evaluation one year later demonstrated that the NDE was not significantly associated with quality of life.

While acknowledging that further studies are needed to confirm these findings in larger cohorts or in survivors of a shorter ICI stay, the authors conclude that "the recall of NDE is not so rare in the ICU." Given that NDEs "are typically reported as transforming and may be associated with , we consider [it] clinically meaningful to interview patients about any potential memory upon awakening," they reveal.

More information: Anne-Françoise Rousseau et al, Incidence of near-death experiences in patients surviving a prolonged critical illness and their long-term impact: a prospective observational study, Critical Care (2023). DOI: 10.1186/s13054-023-04348-2


https://medicalxpress.com/news/2023-04-near-death-icu-survivors.html

'Surgery most effective treatment for metabolic liver disease', says new study

 Metabolic (bariatric) surgery is more effective than medications and lifestyle interventions for the treatment of advanced non-alcoholic fatty liver disease.

A new paper, published today in The Lancet by King's College London and the Catholic University of Rome, is the first to compare three active treatments of  (NASH) and to specifically investigate the effectiveness of  (weight loss surgery) in a randomized clinical trial.

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease, globally affecting 55% of people with type 2 diabetes and 75% of those with obesity. Non-alcoholic steatohepatitis (NASH) is the progressive form of the disease, and is characterized by liver cell injury and inflammation, which induce liver fibrosis (scarring of the tissue). Left untreated, it can lead to  and , and is one of the leading causes of liver transplant in the western world.

NASH also increases risk of cardiovascular disease and overall mortality in patients with obesity or type 2 diabetes. NAFLD/NASH currently affects 12% of adults in the UK; in the U.S. it is estimated that the condition will affect 27 million people by 2030.

The multi-center randomized trial was conducted in Italy. The trial compared the efficacy of bariatric and metabolic surgery versus lifestyle modifications and best current medical care in 288 patients.

Pre- and post-operative liver biopsies showed that surgery was more effective in inducing complete reversal of inflammation and cell damage in the liver—the core characteristics of NASH—without worsening of liver fibrosis after 1 year from surgery. The probability of achieving reversal of NASH was 3–5 times higher with metabolic surgery than with medical care. Surgery was also more effective at achieving improvement of at least one stage of , another pre-specified endpoint of the trial. The two surgical procedures appeared to equally improve NASH.

Researchers say the ability of surgery to control and even improve fibrosis associated with NASH is of special clinical relevance, as fibrosis is the main predictor of liver complications and poor cardiovascular outcomes and death in patients with NASH.

Professor Geltrude Mingrone, first author of the report, Professor of Medicine at the Catholic University of Rome and a Professor of Diabetes and Nutrition at King's College London, said, "The results of our study support the use of metabolic surgery as a treatment of NASH, a condition for long considered orphan of effective therapies."

Professor Francesco Rubino, a senior co-investigator and Chair of Bariatric and Metabolic Surgery at King's College London and consultant surgeon at King's College Hospital, said, "The presence of NASH predicts a significant risk of complications and mortality in people with severe obesity and type 2 diabetes. The results of this study provide a compelling case for prioritization of metabolic surgery in this patient population."

Compared to conventional medical treatment,  also resulted in better overall health benefits. While both surgical procedures seemed to equally improve NASH, the gastric bypass group was more effective than  at improving type 2 diabetes and reducing other cardiovascular risk factors associated with NAFLD/NASH.

More information: Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial, The Lancet (2023).


https://medicalxpress.com/news/2023-04-surgery-effective-treatment-metabolic-liver.html

What Are the Healthiest Drinks for Patients With Type 2 Diabetes?

 Drinking sugar-sweetened beverages (SSBs) increases the risk of cardiovascular disease and all-cause death in people with type 2 diabetes, reveals a US study that also suggests switching to coffee, tea, or low-fat milk may diminish these risks.

The researchers examined data on almost 15,500 participants with type 2 diabetes from two major studies, finding that the highest level of consumption of SSBs was associated with a 20% increased risk of all-cause mortality and a 25% raised risk of cardiovascular disease compared with those who drank the least amounts of these products.

The research, published April 19 in BMJ, also showed that drinking coffee, tea, plain water, and low-fat milk reduced the risk of all-cause death and that switching from SSBs to the other beverages was linked to lower mortality.

"Overall, these results provide additional evidence that emphasizes the importance of beverage choices in maintaining overall health among adults with diabetes," say senior author Le Ma, PhD, Department of Nutrition, Harvard TH Chan School of Public Health, Boston, Massachusetts, and colleagues.

"Collectively, these findings all point in the same direction. Lower consumption of SSBs and higher consumption of coffee, tea, plain water, or low-fat milk are optimal for better health outcomes in adults with type 2 diabetes," Nita G. Forouhi, MD, PhD, emphasizes in an accompanying editorial.

Choice of Drink Matters

Forouhi, from the University of Cambridge School of Clinical Medicine, UK, warned, however, that the findings "cannot be considered cause and effect," despite the large-scale analysis.

Moreover, "questions remain," such as the impact of beverage consumption on coronary heart disease and stroke risk, and cancer mortality, with the current study providing "inconclusive" data on the latter.

There was also no data on the addition of sugar to tea or coffee, "so the comparative health effects of unsweetened and sweetened hot beverages remain unclear," Forouhi points out. Also unknown is whether the type of tea consumed has a differential effect.

Despite these and other reservations, she says that overall, "Choice of beverage clearly matters."

"The case for avoiding sugar-sweetened beverages is compelling, and it is supported by various fiscal measures in more than 45 countries. It is reasonable to shift the focus to drinks that are most likely to have positive health impacts: coffee, tea, plain water, and low-fat milk," she notes.

Forouhi ends by underlining that the current findings tally with those seen in the general population, so "one important message is that having diabetes does not have to be especially restrictive."

Expanding the Evidence

It was estimated that 537 million adults worldwide had type 2 diabetes in 2021, a figure set to increase to 783 million by 2045, say the authors.

Individuals with type 2 diabetes have an increased risk of cardiovascular disease, among many other comorbidities, as well as premature death. Dietary interventions can play an important role in managing these risks.

Recommendations on the healthiest beverages to drink are largely based on evidence from the general population, and data are limited on the best options for adults with type 2 diabetes, who have altered metabolism, the researchers note.

To expand on this, they examined data from the Nurses' Health Study, which enrolled female registered nurses aged 30-55 years and was initiated in 1976, and the Health Professionals Follow-Up Study, which included male health professionals aged 40-75 years and was initiated in 1996.

For the current analysis, 11,399 women and 4087 men with type 2 diabetes were included from the two studies, of whom 2715 were diagnosed before study entry.

Participants' average daily beverage intake was assessed using a validated food frequency questionnaire administered every 2-4 years. SSBs included caffeinated and caffeine-free colas, other carbonated SSBs, and noncarbonated SSBs, such as fruit punches, lemonades, or other fruit drinks.

During 285,967 person-years of follow-up, there were 7638 (49.3%) deaths, and 3447 (22.3%) cases of incident cardiovascular disease were documented during 248,447 person-years of follow-up.

Fully adjusted multivariate analysis comparing the lowest and highest beverage intake indicated that SSBs were associated with a significant increase in all-cause mortality, at a pooled hazard ratio (HR) of 1.20, or 1.08 for each additional serving per day (P = .01).

In contrast, the associations between all-cause mortality and consumption of artificially sweetened beverages, fruit juice, and full-fat milk were not significant, whereas coffee (HR, 0.74), tea (HR, 0.79), plain water (HR, 0.77), and low-fat milk (HR, 0.88) were linked to a reduced risk.

The team reported that there were similar associations between beverage intake and cardiovascular disease incidence, at an HR of 1.25 for SSBs, as well as for cardiovascular disease mortality, at an HR of 1.29.

Participants who increased their tea, coffee, and low-fat milk consumption during the course of the study had lower all-cause mortality than those who did not. Switching from SSBs to other beverages was also associated with lower mortality.

The researchers note, however, that there are "several potential limitations" to their study, including that "individual beverage consumption may be correlated with other dietary and lifestyle risk factors for cardiovascular disease incidence and mortality among adults with [type 2] diabetes."

The study was sponsored by the National Institutes of Health. Sun has reported no relevant financial relationships. Disclosures for the other authors are listed with the article. Forouhi has declared receiving support from the UK Medical Research Council Epidemiology Unit and UK National Institute for Health and Care Research Biomedical Research Centre Cambridge.

BMJ. 2023;381:e073406. Full textEditorial

https://www.medscape.com/viewarticle/991008

Why Tenaya Caught Fire

 Shares of the clinical-stage gene therapy company Tenaya Therapeutics (TNYA 24.96%) rose by a staggering 49% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The biotech's shares caught fire in response to a wave of bargain buying in biotech, sparked by the buyouts of BELLUS Health and Prometheus Biosciences for enormous premiums earlier this week. 

Tenaya is an early-stage gene therapy player focusing on the development of treatments for heart disease. Recently, the company won an approval from the Food and Drug Administration (FDA) to begin a phase 1b trial for TN-201 as a potential treatment for hypertrophic cardiomyopathy (HCM) caused by mutations in the MYBPC3 gene. This mutation is the most common genetic cause of HCM, according to the company.

Wall Street analysts are expecting big things from the small-cap gene therapy company. Underscoring this point, the consensus 12-month price target on Tenaya's stock implies an upside potential of 370% from current levels. With this bargain proposition in mind, it's not surprising to see shares perk up as investors hunt for deals in the out-of-favor biotech space. 

Is Tenaya stock still a buy? It all depends on your comfort with risk. It is far from the first biotech to try to use a gene therapy to treat various forms of heart disease. So far, though, this cutting-edge approach hasn't yielded much in the way of positive results.

That doesn't mean that Tenaya can't succeed where others have failed, but this is a high-risk growth play to be sure. 

https://www.fool.com/investing/2023/04/20/why-this-nasdaq-stock-caught-fire-this-week/

BullFrog AI Partners with Sage Group on JV Opportunities for Oncology Assets

 BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, today announced a strategic partnership with the Sage Group (www.sagehealthcare.com), a leader in the provision of strategic and transactional advice to healthcare and life science companies in the pharmaceutical, diagnostics, medical device, biotech, regenerative medicine, and cell and gene therapy fields.

The engagement will focus on seeking joint venture (JV) opportunities to further advance BullFrog AI’s Phase 2 ready asset targeting glioblastoma, an aggressive form of brain cancer, as well as the Company’s preclinical prodrug asset. The partnership will give BullFrog AI access to the Sage Group’s clinical and regulatory expertise, capital resources, and network of contacts, including innovators and large pharma.

https://finance.yahoo.com/news/bullfrog-ai-partners-sage-group-110000913.html